IN2015DN03331A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03331A
IN2015DN03331A IN3331DEN2015A IN2015DN03331A IN 2015DN03331 A IN2015DN03331 A IN 2015DN03331A IN 3331DEN2015 A IN3331DEN2015 A IN 3331DEN2015A IN 2015DN03331 A IN2015DN03331 A IN 2015DN03331A
Authority
IN
India
Prior art keywords
sina
betahydroxysteroid
dchydrogenase
isd1
beta
Prior art date
Application number
Other languages
English (en)
Inventor
Antón Ana Isabel Jiménez
Angela Sesto Yague
GÓMEZ Ma Concepción JIMÉNEZ
Original Assignee
Sylentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sa filed Critical Sylentis Sa
Publication of IN2015DN03331A publication Critical patent/IN2015DN03331A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01146—11-Beta-hydroxysteroid dehydrogenase (1.1.1.146)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3331DEN2015 2005-10-25 2006-10-25 IN2015DN03331A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0521716.1A GB0521716D0 (en) 2005-10-25 2005-10-25 Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
PCT/GB2006/050352 WO2007049074A2 (en) 2005-10-25 2006-10-25 Modulation of 11beta-hydroxysteroid dehydrogenase 1 expression for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
IN2015DN03331A true IN2015DN03331A (enExample) 2015-10-23

Family

ID=35458653

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3331DEN2015 IN2015DN03331A (enExample) 2005-10-25 2006-10-25

Country Status (12)

Country Link
US (1) US8188057B2 (enExample)
EP (2) EP1941037B1 (enExample)
JP (2) JP5398262B2 (enExample)
CN (1) CN101346467B (enExample)
AU (1) AU2006307690B2 (enExample)
CA (1) CA2627272C (enExample)
ES (1) ES2403305T3 (enExample)
GB (1) GB0521716D0 (enExample)
IN (1) IN2015DN03331A (enExample)
MX (1) MX2008005409A (enExample)
RU (1) RU2420582C2 (enExample)
WO (1) WO2007049074A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
WO2009073460A2 (en) * 2007-12-03 2009-06-11 Bausch & Lomb Incorporated Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection
CN101969282A (zh) * 2010-10-25 2011-02-09 北京印刷学院 抛物柱面聚光凹形闭合腔体采光太阳能发电装置
CN101976979A (zh) * 2010-10-25 2011-02-16 北京印刷学院 抛物柱面聚光半圆柱面闭合腔体采光太阳能发电装置
HRP20191600T1 (hr) * 2013-09-13 2019-11-29 Ionis Pharmaceuticals Inc Modulatori faktora b komplementa
MA44908A (fr) * 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
CN106702003B (zh) * 2017-02-28 2021-02-12 固安博健生物技术有限公司 Hsdl1在诊治骨肉瘤中的应用
CN109022436B (zh) * 2018-06-07 2021-04-09 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 特异抑制3β-HSD基因表达的shRNA重组载体构建与应用
JP6617191B1 (ja) * 2018-12-03 2019-12-11 三井金属鉱業株式会社 溶液中の目的成分を分離又は分析するための方法及び装置
CN120204234B (zh) * 2025-05-28 2025-08-19 温州医科大学附属眼视光医院 11β-HSD1通路活性抑制剂在制备治疗青光眼睫状体炎综合征药物上的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) * 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) * 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) * 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) * 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) * 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) * 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6365576B1 (en) * 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003059267A2 (en) * 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8202845B2 (en) 2002-04-18 2012-06-19 Acuity Pharmaceuticals, Inc. Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
US20040115815A1 (en) 2002-07-24 2004-06-17 Immusol, Inc. Single promoter system for making siRNA expression cassettes and expression libraries using a polymerase primer hairpin linker
WO2004009794A2 (en) 2002-07-24 2004-01-29 Immusol, Inc. NOVEL siRNA LIBRARIES AND THEIR PRODUCTION AND USE
EP1527176B2 (en) 2002-08-05 2017-03-22 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
KR20050083855A (ko) 2002-11-01 2005-08-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US20040167090A1 (en) * 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) * 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2004097002A2 (en) * 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
US7462602B2 (en) * 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) * 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
DE10322539A1 (de) 2003-05-19 2004-12-09 Siemens Ag Verfahren zum Aufbau einer Kommunikationsverbindung und Kommunikationssystem
EP1636342A4 (en) 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMER COMPOUNDS FOR USE IN THE MODULATION OF GENES
WO2005034870A2 (en) 2003-10-07 2005-04-21 Renovis, Inc. Amide compounds and ion channel ligands and uses thereof
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
AU2005222902B2 (en) * 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
CA2576233C (en) * 2004-08-10 2016-03-15 Alnylam Pharmaceuticals, Inc. Conjugate comprising an antagomir and a ligand
RU2407531C2 (ru) * 2004-08-23 2010-12-27 Силентис С.А.У. ЛЕЧЕНИЕ ГЛАЗНЫХ БОЛЕЗНЕЙ, ОТЛИЧАЮЩИХСЯ ПОВЫШЕННЫМ ВНУТРИГЛАЗНЫМ ДАВЛЕНИЕМ, С ПОМОЩЬЮ siPHK
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
AU2006223131A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

Also Published As

Publication number Publication date
GB0521716D0 (en) 2005-11-30
AU2006307690B2 (en) 2012-07-12
WO2007049074A3 (en) 2007-08-02
MX2008005409A (es) 2008-11-26
US8188057B2 (en) 2012-05-29
HK1120830A1 (en) 2009-04-09
RU2420582C2 (ru) 2011-06-10
CN101346467B (zh) 2013-03-13
CN101346467A (zh) 2009-01-14
EP1941037B1 (en) 2013-01-16
US20110160277A1 (en) 2011-06-30
CA2627272C (en) 2015-12-01
WO2007049074A2 (en) 2007-05-03
AU2006307690A1 (en) 2007-05-03
CA2627272A1 (en) 2007-05-03
JP5398262B2 (ja) 2014-01-29
EP1941037A2 (en) 2008-07-09
JP2009513617A (ja) 2009-04-02
RU2008120702A (ru) 2009-12-10
JP2013176395A (ja) 2013-09-09
ES2403305T3 (es) 2013-05-17
EP2354229A3 (en) 2012-12-05
EP2354229A2 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
TW200637866A (en) Amino-imidazolones for the inhibition of β-secretase
TW200640924A (en) VEGF-R2 inhibitors and methods
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
WO2007092622A3 (en) Compositions and methods for treating bone
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
TW200719892A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MX351401B (es) Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
IL190730A0 (en) Potassium channel inhibitors
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008073332A3 (en) Creatine compositions for skin treatment
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
TW200724140A (en) Hydantoin compounds
UA86119C2 (ru) Амидные пролекарства гемцитабина, их композиции и применение
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
IN2015DN03331A (enExample)
UA96265C2 (ru) Композиция и способ ингибирования jak пути передачи сигнала
WO2004060878A3 (en) Inhibitors of phosphatases
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof